Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults

Vaccine

Volumn 14, Issue 15, 1996, Pages 1407-1411

  Bruguera, Miquel ^a   Bayas, José María ^a   Vilella, Ana ^a   Tural, Cristina ^a   González, Antonio ^b   Vidal, Josep ^a   Dal Ré, Rafael ^b   Salleras, Lluis ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

HAV; HBV

Indexed keywords

HEPATITIS B VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEADACHE; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HEPATITIS ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; MALE; QUALITY CONTROL; VACCINES, COMBINED; VIRAL HEPATITIS VACCINES;

EID: 0030448190     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00089-8     Document Type: Article

References (33)

1. 1 Szmuness, W., Stevens, C.E., Harley, E.J. et al. Hepatitis B vaccine: demostration of efficacy in a controlled clinical trial in a high risk population in the United States. N. Engl. J. Med. 1980, 303, 833-841
2. 2 Francis, D.P., Hadler, S.C., Thompson, S.E. et al. Prevention of hepatitis B with vaccine: report from the Centers for the Disease Control multi-center efficacy trial among homosexual men. Ann. Intern. Med. 1982, 97, 362-366
3. 3 Poovorawan, Y., Sanpavat, S., Pongpunlert, W., Chumdermpadetsuk, S., Sentrakul, P. and Safary, A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. J. Am. Med. Assoc. 1989, 261, 3278-3281
4. 4 Hadler, S.C., Francis, D.P., Maynard, J.E. et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 1986, 315, 209-214
5. 5 Wainwright, R.B., McMahon, B.J., Bulkow, L.S. et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. J. Am. Med. Assoc. 1989, 261, 2362-2366
6. 6 Milne, A., Hopkirk, N. and Moves, C.D. Hepatitis B vaccination in children: persistence of immunity at 9 years. J. Med. Virol. 1994, 44, 113-114
7. 7 Alter, M.J., Hadler, S.C., Margolis, H.S. et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. J. Am. Med. Assoc. 1990, 263, 1218-1222
8. 8 Centers for Disease Control Recomendations of the Immunization Practices Advisory Committee (ACIP). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Morbid. Mortal. Wkly Rep. 1991, 40RR-13, 1-25
9. 9 WHO Expanded programme on immunization. Global Advisory Group. EPI for the 1990's. Wkly Epidemiol. Rec. 1992, 3, 12-13
10. 10 WHO Working Group. Control of viral hepatitis in Europe. Munich, April 1991. Regional Office for Europe, Copenhagen. EUR/ICP/OCD 016, 1992
11. 11 American Academy of Pediatrics Committe on Infectious Diseases. Universal Hepatitis B immunization. Pediatrics 1992, 89, 795-800
12. 12 Werzberger, A., Mensch, B., Kuter, B. et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in children. N. Engl. J. Med. 1992, 327, 453-457
13. 13 Innis, B.L., Snitbhan, R., Kunasol, P. et al. Protection against hepatitis A by an inactivated vaccine. J. Am. Med. Assoc. 1994, 271, 1328-1334
14. 14 Bruguera, M. and Sanchez-Tapias, J.M. Epidemiologia de la hepatitis B en España. Med. Clin. (Barc.) 1990, 95, 470-475
15. 15 Salleras, L., Bruguera, M., Vidal, J. et al. Prevalence of hepatitis B markers in the population of Catalonia (Spain). Rationale for universal vaccination of adolescents. Eur. J. Epidemiol. 1992, 8, 640-644
16. 16 Papaevangelou, G. Epidemiology of hepatitis A in Mediterranean countries. Vaccine 1992, 10Suppl. 1, S63-S66
17. 17 Pasquini, P., Mele, A. and Stazi, M.A. The importance of heterosexual transmission of hepetitis B in Italy. In: Hepatitis B: a Sexually Transmitted Disease in Heterosexuals (Eds Piot, P. and Andre, F.E.). Elsevier Science Publishers BV, Amsterdam, 1990, pp. 23-29
18. 18 D'Amelio, R., Matricardi, P.M., Biselli, R. et al. Changing epidemiology of hepatitis B in Italy: public health implications. Am. J. Epidemiol. 1992, 135, 1012-1018
19. 19 Hadler, S.C. Global impact of hepatitis A virus infection changing patterns. In: Viral Hepatitis and Liver Disease (Eds Hollinger, F.B., Lemon, S.M. and Margolis, H.S.). Williams and Wilkins, Baltimore, 1991, pp. 14-20
20. 20 Perez-Trallero, E., Cilla, G., Urbieta, M., Dorronsoro, M., Otero, F. and Marimon, J.M. Falling incidence and prevalence of hepatitis A in Northern Spain. Scand. J. Infect. Dis. 1994, 26, 133-136
21. 21 González, A., Bruguera, M., Calbo, F. et al. Encuesta epidemiológica de prevalencia de anticuerpos antihepatitis A en población adulta joven española. Med. Clin. (Barc.) 1994, 103, 445-448
22. 22 André, F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am. J. Med. 1989, 87Suppl. 3A, 14S-20S
23. 23 André, F.E., D'Hondt, E., Delem, A. and Safary, A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992, 10Suppl. 1, S160-S168
24. 24 Ambrosch, F., Andre, F.E., Delem, A. et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine 1992, 10Suppl. 1, S142-S145
25. 25 Ayoola, E.A. Viral hepatitis in Africa in the 90s: facing realities. In: Viral Hepatitis and Liver Disease (Eds Nishioka, K., Suzuki, H., Mishiro, S. and Oda, T.). Springer-Verlag, Tokyo, 1994, pp. 381-384
26. 26 Engerix-B. Hepatitis B vaccine (rby). Havrix; Hepatitis A vaccine HM 175 strain. ABPI Data Sheet Compendium 1993-94. Datapharm Publications Ltd, London, 1993, pp. 1574-1576
27. 27 Vaccin Havrix 720 U/1 ml. Vaccin inactivé contre l'hepatite A. Vidal 1994, 70th Edn. Editions du Vidal, Paris, 1994, pp.1539-1540
28. 28 Engerix-B. Hepatitis B vaccine (Recombinant). Physicians' Desk Reference 1995, 49th Edn. Medical Economics Data Production Company, Montvale, NJ, 1995, pp. 2371-2373
29. 29 Bruguera, M., Vidal, J. and Rodes, J. Factores de riesgo en la hepatitis A de los adultos. Gastroenterol. Hepat. 1992, 15, 129-133
30. 30 Margolis, H.S., Hadler, S.C., Shapiro, C.N. and Alter, M.J. Immunization strategies for the control of hepatitis A in the United States. In: Viral Hepatitis and Liver Disease (Eds Hollinger, F.B., Lemon, S.M. and Margolis, H.S.). Williams and Wilkins, Baltimore, 1991, pp. 724-726
31. 31 Wong, V.K., Woodruff, C. and Shapiro, R. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic. Pediatr. Infect. Dis. 1994, 13, 936
32. 32 Ministére des Affaires Sociales de la Santé et de la Ville. Nouvelles mesures sur la vaccination contre l'hepatite B. 6 juillet 1994. Ministére de L'Education Nationale. Vaccination des élèves des colleges contre l'Hepatite virale B. Paris, 16 Novembre 1994
33. 33 Van Damme, P., Thoelen, S., Cramm, M. and Meheus, A. Persistance of the antibody response to an inactivated Hepatitis A vaccine. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 4-7 October 1994, Orlando, FL, USA. American Society for Microbiology. Abstract No. H117